EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Diagnostic and prognostic value of RUNX1 in ovarian serous cystadenocarcinoma and its role in cancer progression via suppressing ferroptosis

Deng He, Yu Zhou, Tiantian Feng, Hu Wang, Nenghuan Tang, Shangqi Ni, Wang Xi, Chengju Zhang

Postępy Higieny i Medycyny Doświadczalnej · 01.01.2026 · 80 (1) · 17-29

DOI: 10.2478/ahem-2026-0003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Postępy Higieny i Medycyny Doświadczalnej, online erschienen am 02.03.2026. Verfasst von Deng He und 7 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We explore the clinical and prognostic significance of RUNX1 in ovarian serous cystadenocarcinoma (OSC) and report its previously unreported role in regulating ferroptosis. Materials and Methods RUNX1 expression and prognosis were tested using TCGA-OV and GTEx data. Functional roles were assessed in vitro via RUNX1 knockdown in OSC cell lines, while measuring proliferation (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) and colony formation) and ferroptosis sensitivity (erastin treatment and glutathione/malondialdehyde (GSH/MDA) assays). Mechanisms were explored via western blotting and bioinformatic analysis.

Results

RUNX1 was significantly higher in OSC patients and correlated to poor overall survival, thereby indicating its prognostic value. RUNX1 knockdown suppressed proliferation and increased erastin-induced ferroptosis sensitivity. Silencing RUNX1 reduced GSH, elevated MDA, and inhibited Nrf2 signaling, thus, suggesting ferroptosis regulation via this pathway.

Conclusion

RUNX1 is an independent prognostic biomarker for OSC. Crucially, we provide novel evidence that RUNX1 promotes OSC progression by conferring resistance to ferroptosis likely through the Nrf2 pathway. Thus, targeting the RUNX1-ferroptosis axis represents a promising therapeutic strategy.

Zitieren

APA

He, D., Zhou, Y., Feng, T., Wang, H., Tang, N., Ni, S., Xi, W., & Zhang, C. (2026). Diagnostic and prognostic value of RUNX1 in ovarian serous cystadenocarcinoma and its role in cancer progression via suppressing ferroptosis. Postępy Higieny i Medycyny Doświadczalnej, 80(1), 17-29. https://doi.org/10.2478/ahem-2026-0003

Vancouver

He D, Zhou Y, Feng T, Wang H, Tang N, Ni S, et al. Diagnostic and prognostic value of RUNX1 in ovarian serous cystadenocarcinoma and its role in cancer progression via suppressing ferroptosis. Postępy Higieny i Medycyny Doświadczalnej. 2026;80(1):17-29. doi:10.2478/ahem-2026-0003

BibTeX
@article{He2026,
  author = {He, Deng and Zhou, Yu and Feng, Tiantian and Wang, Hu and Tang, Nenghuan and Ni, Shangqi and Xi, Wang and Zhang, Chengju},
  title = {Diagnostic and prognostic value of RUNX1 in ovarian serous cystadenocarcinoma and its role in cancer progression via suppressing ferroptosis},
  journal = {Postępy Higieny i Medycyny Doświadczalnej},
  year = {2026},
  volume = {80},
  number = {1},
  pages = {17--29},
  doi = {10.2478/ahem-2026-0003}
}
Kostenlos starten →